Lorvotuzumab mertansine

N/A

Report date: 2024/02/05 13:57:18

Base Information

Drug NameLorvotuzumab mertansine
Drug Alias NamehuN-901-DM1 antibodyBB-10901huN-901-SPP-DM1IMGN-901-TAPhuN-901-DM1 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPP linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsNeural cell adhesion molecule 1 inhibitors
TargetsNeural cell adhesion molecule 1Tubulin
Therapy Area/IndicationsSmall Cell Lung CarcinomaOvarian NeoplasmsMultiple Myeloma +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesArgentina +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterImmunogen Inc
Active IndicationsNeuroblastomaRhabdomyosarcomaSarcoma, Synovial +[6] 
Inactive IndicationsSmall Cell Lung CarcinomaOvarian NeoplasmsMultiple Myeloma +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG